Thales, European Leader in Quantum Physics and Artificial Intelligence, Opens InnovDays 2019
Thales launched InnovDays in 2012 as a way for its customers and partners to gain exclusive insights into the technological excellence of its research facilities. Since then, successive InnovDays events have turned the spotlight on the latest technological innovations developed by more than 29,500 Thales engineers and researchers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191127005575/en/
Thales InnovDays 2019 (Photo: Thales)
InnovDays: building a trusted future through science
InnovDays is a reflection of Thales's objective of leveraging science and high technology to build a future we can all trust. By harnessing the unprecedented precision and power of quantum physics and augmenting the performance of its systems thanks to artificial intelligence, Thales is developing the new generation of technologies that will shape the world of tomorrow.
"InnovDays is an illustration of Thales's outstanding technological capabilities and the passion displayed by our 29,500 engineers for helping our customers step up to society's major challenges through innovation." Marko Erman, Chief Technology Officer.
As an expert in critical systems, Thales is conducting in-depth research into both digital technologies and deep tech solutions to develop a portfolio of products based on a common core of technological building blocks. At InnovDays on 27, 28 and 29 November 2019, Thales will present a total of 70 practical applications of this research centred around the following themes:
Round tables:
-
Thursday 28 November:
- 8.30 am: How can we make AI trustable?
- 1.30 pm: Sovereignty in the digital age
-
Friday 29 November:
- 8.30 am: High tech and climate change: friend or foe?
- 11.00 am: The strategy and the future of air transport
- 1.30 pm: The second quantum revolution starts now!
Star guests from the world of science and industry will be taking part in these round table sessions, including Albert Fert (Nobel Prize in Physics 2007), Jean-Marc Jancovici (Founder and President of The Shift Project), Alexandre de Juniac (IATA Director General and CEO) and Pascale Senellart (research director at the Centre for Nanoscience and Nanotechnology, Paris-Saclay University, Paris-Sud University, CNRS).
Proposed press tours at InnovDays 2019
- Tomorrow's cities
- The future of transport
- Biometrics
- The Cloud
- Big Data
- Tomorrow's connectivity in the civil world
- Tomorrow's connectivity in the world of defence
- Air defence of the future
- Land and naval defence of the future
- The augmented soldier
- Secure identities and data for citizens and businesses
|
On 27, 28 and 29 November 2019, the Thales YouTube channel will feature live coverage of the round table sessions and some of the most popular demonstrations. |
From sensors that are up to 10,000 more accurate to ultra-secure communications, quantum technologies are set to push back the boundaries of physics and unleash previously unexploited properties of matter.
An aircraft flying from Paris to New York with only an inertial navigation system to guide it could determine its location to within a few kilometres. With future quantum sensors, it could land with a precision of within a metre. In other fields, quantum sensors could detect tumours that are invisible today, or provide a basis for developing new sources of energy.
Quantum physics relies on radically new concepts and ways of manipulating matter. Quantum sensors, like quantum communications and quantum computing, are currently under the microscope in the laboratories operated by Thales and its academic partners (CNRS, Université Paris-Saclay, etc.) at the Saclay research and technology cluster, south of Paris.
On 26 November 2019, Thales and its academic and research partners are organising a presentation at Saclay to highlight European excellence in quantum research: from cold atoms to flawed diamonds and superconductors, scientific progress in quantum physics has the potential to harness unexploited properties of matter and unleash a whole host of new opportunities.
Thales is working on these new properties to develop the next generation of quantum sensors, relying on the exact same technological building blocks as quantum computers. Quantum encryption too, could soon lead to communication systems that are completely secure and trustworthy.
Thales has also been selected to take part in the European OPENQKD initiative as part of the Austrian Institute of Technology (AIT) consortium chosen by the European Commission to install infrastructure in several European countries to test quantum communication networks.
Navigating intelligently among millions of aircraft movements: Thales presents the brain of tomorrow's aircraft.
Ultimately, quantum technologies will provide untold benefits for avionics systems, including order-of-magnitude improvements in navigation precision. But the immediate truth is that solutions are needed now to deal with the growth in air traffic, which is expected to have doubled by 2030.
This is the thinking behind PureFlyt, developed by Thales as the brain of tomorrow's aircraft, a fully connected cockpit that will significantly increase aircraft performance.
PureFlyt will be unveiled in Toulouse on 25 November. One of the core innovations that makes PureFlyt a game-changer is its ability to draw on both onboard and open-world data, such as weather information, so that the aircraft trajectory can be permanently controlled, adapted and enhanced, resulting in optimised flight, decreased fuel consumption and a better flying experience for both passengers and crew.
|
About Thales Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 80,000 employees in 68 countries, Thales generated sales of €19 billion in 2018 (on a pro forma basis including Gemalto). Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments. |
PLEASE VISIT
Thales Group
Download photos
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191127005575/en/
Contact information
PRESS
Thales, Media relations
Cédric Leurquin
+33 (0)1 57 77 90 93
cedric.leurquin@thalesgroup.com
Thales, Media relations
Alice Pruvot
+331 57 77 89 52
alice.pruvot@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
